Skip to main content
Log in

Fibrinolytic activity of earthworms extract (g-90) on lysis of fibrin clots originated from the venous blood of patients with malignant tumors

  • Article
  • Published:
Pathology & Oncology Research

Abstract

u-PA is secreted by the most malignant tumors. As a response to u-PA synthesis surrounding cells synthetize inhibitors of plasminogen activators for tissue protection. Plasminogen activators were found also in earthworm tissue. From the tissue homogenate of earthworm Eisenia foetida the glycolipoprotein mixture named G-90 was isolated. It contains two serine proteases (P I, P II) with fibrinolytic and anticoagulative activities. The fibrinolytic activity of G-90, P I and P II was tested in an in vitro euglobulinic test applied to fibrin clot from blood plasma of patients suffered from malignant tumors. G-90 and above-mentioned proteases applied in this study showed euglobulinic time proportionally with the concentrations of added substances. The influence of G-90 on the fibrinolysis rate does not depend only on its concentration, but depends too on histological type of tissue (organ) where the malignant tumors are located. Enzyme P I and P II do not show this activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Brommer EJP,Emeis JJ,Verheijen JH,et al: Progress in Clinical Fibrinolysis. In: 7 Recent Advances in Blood Coagulation. (Eds. Poller L and Ludlam CA), Churchill Livingstone, 1997, pp. 161-182.

  2. Bugge TH, Flick MJ, Danton MJ, et al: Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 93:5899–5904, 1996.

    Article  PubMed  CAS  Google Scholar 

  3. Cooper DL, Sandler AB, Wilson LD, et al: Disseminated Intravascular Coagulation and Excessive Fibrinolysis in a Patient with Metastatic Prostate Cancer. Cancer 70:656–658, 1992.

    Article  PubMed  CAS  Google Scholar 

  4. Driscoll J and Goldberg AL: The proteasome (multicatalytic protease) is a component of the 1500 kDa proteolytic complex which degrades ubiquitin-conjugated proteins. J Biol Chem 265:4789–4792, 1990.

    PubMed  CAS  Google Scholar 

  5. Gandolfo GM, Conti L and Vercillo M: Fibrinolysis Components as Prognostic Markers in Breast Cancer and Colorectal Carcinoma. Anticancer Res 16:2155–2160, 1996.

    PubMed  CAS  Google Scholar 

  6. Gabazza EC, Taguchi O, Yarnakami T, et al: Coagulation-Fibrinolysis System and Markers of Collagen Metabolism in Lung Cancer. Cancer 70:2631–2636, 1992.

    Article  PubMed  CAS  Google Scholar 

  7. Gabazza EC, Taguchi O, Yamakami T, et al: Evaluating prethrombotic state in lung cancer using molecular markers. Chest 103:196–200, 1993.

    Article  PubMed  CAS  Google Scholar 

  8. Gailani D and Broze GJ: Regulation of coagulation by tissue factor pathway inhibitor. In: 7 Recent Advances in Blood Coagulation. (Eds. Poller L and Ludlam CA), Churchill Livingstone, 1997, pp. 1-17.

  9. Hanss M, Bonvoisin C, Patouillard B, et al: Increased plasma levels of urokinase type plasminogen activator during hepatocellular carcinoma. Fibrinolysis 8:255–260, 1994.

    Article  Google Scholar 

  10. Hrženjak T, Hrženjak M, Kašuba V, et al: A new source of biologically active compounds-earthworm tissue (Eisenia foetida, Lumbricus rubelus). Comp Biochem Physiol I02A:44I-447, 1992.

    Google Scholar 

  11. Hrženjak M, Kobrehel D, Levanat S, et al: Mitogenicity of the earthworm’s (Eisenia foetida) insulin-like proteins. Comp Biochem Physiol 104B:723–729, 1993.

    Google Scholar 

  12. Hrženjak T,Popovic M,Bozič T,et al. Fibrinolytic and antico-agulative activities from the earthworm Eisenia foetida. Comp Biochem Physiol, in press, 1998.

  13. Inndorf S, Bechtel MJ, Reinartz J, et al: Cell density-dependent downregulation of urokinase-type plasminogen activator in normal but not in ransformed human epidermal keratinocytes. Arch Dermatol Res 288,783–785, 1996.

    Article  PubMed  CAS  Google Scholar 

  14. Jeon OH, Moon WJ and Kim DS: An anticoagulant/fibrinolytic protease from Lumbricus rubellus. J Biochem Mol Biol 28:138–142,1995.

    CAS  Google Scholar 

  15. Kramer MD, Schaefer B and Reinartz J: Plasminogen activation by human keratinocytes: molecular pathways and cell-biological consequences. Biol Chem 373:131–141, 1995.

    Google Scholar 

  16. Massignon D, Lepape A, Bienvenu J, et al: Coagulation fibrinolysis balance in septic shock related to cytokines and clinical state. Haemostasis 24:36–48, 1994.

    PubMed  CAS  Google Scholar 

  17. Mihara H, Sumi H, Mizumoto H, et al: Oral administration of erthworm power as a possible thrombolytic therapy. Recent Advances in Thrombosis and Fibrinolysis (Ed Tanaka K): 287–298. Academic Press New York 1990.

    Google Scholar 

  18. Mihara H, Sumi H, Yoneta T, et al: A Novel fibrinolytic enzyme extracted from the earthworm Lumbricus rubellus. Jap J Physiol 41: 461–472,1991.

    Article  CAS  Google Scholar 

  19. Nakajima N, Mihara H and Sumi H: Characterisation of potent fibrinolytic enzymes in earthworm, Lumbricus rubellus. Biosci Biotech Biochem 57:1726–1730, 1993.

    Article  CAS  Google Scholar 

  20. Popović M, Tiska-Rudman LJ and Hrženjak T: Tissue extract of earthworm Eisenia foetida (G-90) as a blood anticoagulant and fibrinolytic. Vet Arhiv 66:161–167, 1996.

    Google Scholar 

  21. Popović M, Grdiša M, Vuković S, et al: Adhesins of immunoglobulin-like superfamily from earthworm Eisenia foetida. Gen Pharmacol 30:795–800,1997.

    Article  Google Scholar 

  22. Prasad KSM, Sharma BS, Marwaha N, et al: Haemostatic derangement in patients with intracranial tumours. Br J of Neurosurg 8:695–702, 1994.

    Article  CAS  Google Scholar 

  23. Sagripanti A,Capri A and Zacharski LR: The pathophysiology of the haemostatic system in cancer patients: Insights gained from studies using plasmatic markers of haemostatic system activation. In: Cancer and Blood Coagulation: basic and clinical aspect. (Eds: Sagripanti A, Carpi A and Zacharski LR), Ets Editrice, 1990, pp 69-92.

  24. Schaefer BM, Stark HJ, Fusenig NE, et al: Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system. Experimental Cell Res 220:415–423, 1995.

    Article  CAS  Google Scholar 

  25. Salgado A, Boveda JE, Monasterio J, et al: Inflammatory Mediators and Their Influence on Haemostasis. Haemostasis 24:132–138, 1994.

    PubMed  CAS  Google Scholar 

  26. See WA, Yong X, Crist S, et al: Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines. J Urology 151:1691–1696, 1994.

    CAS  Google Scholar 

  27. Van-Duijnhoven EM, Lustermans FAT and Van-Wersch JWJ: Evaluation of the coagulation/fibrinolysis balance in patients with colorectal cancer. Haemostasis 23:168–172, 1993.

    PubMed  Google Scholar 

  28. Wojtukiewich MZ, Zacharski ER, Memoli VA, et al: Interaction with Coagulation and Fibrinolysis Pathways In Situ. Am J Clin Path 93:516–521, 1990.

    Google Scholar 

  29. Zhu CE, Zhang GH, Duan Y, et al: A clinical observation on the treatment of cerebral infarction with Eisenia foetida enzyme. Acta Acad Med Shanghai 20:447–450, 1993.

    CAS  Google Scholar 

  30. Yang JS and Ru BG: Purification and characterisation of a SDS-activated fibrinolytic enzyme from Eisenia fetida. Comp Biochem Physiol 118B:623–631, 1997.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Terezija M HrŽenjak.

Rights and permissions

Reprints and permissions

About this article

Cite this article

HrŽenjak, T.M., PopoviĆ, M. & TiŠka-rudman, L. Fibrinolytic activity of earthworms extract (g-90) on lysis of fibrin clots originated from the venous blood of patients with malignant tumors. Pathol. Oncol. Res. 4, 206–211 (1998). https://doi.org/10.1007/BF02905250

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02905250

Key words

Navigation